Chemotakas - Company finances
|
EUR
|
2021
From: 2021-05-10
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 8,050 | 34,158 | 28,472 | 2,500 | 4,500 |
| Profit before tax | 206 | 21,203 | 1,190 | -15,065 | -3,395 |
| Net profit | 206 | 20,143 | 1,131 | -15,065 | -3,395 |
| Equity | 206 | 20,349 | 21,480 | 6,415 | 3,020 |
| Liabilities | - | 1,360 | 559 | 0 | 0 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 4,406 | 21,709 | 22,039 | 6,415 | 3,020 |
| Total assets | 4,406 | 21,709 | 22,039 | 6,415 | 3,020 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 1,060 | 60 | - |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +324.3% | -16.6% | -91.2% | +80.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.7% | 92.8% | 5.1% | -234.8% | -112.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 99.0% | 5.3% | -234.8% | -112.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.6% | 59.0% | 4.0% | -602.6% | -75.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 2.6% | 62.1% | 4.2% | -602.6% | -75.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.1 | 0.0 | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Chemotakas - Social security debts
The company had no debts to Sodra
Chemotakas - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Chemotakas, MB (code 305762630) is a Small partnership active in engineering design and construction activities. In 2025, the company generated revenue of €4.5K and recorded a net loss of €3.4K, producing a profit margin of -75.4%. Profitability remained under pressure after a much weaker 2024, when revenue fell to €2.5K and the net loss widened to €15.1K, compared with 2023, when revenue reached €28.5K and net profit was €1.1K. Over the two-year period from 2023 to 2025, revenue declined materially overall, despite an 80.0% year-on-year increase in 2025 from the low 2024 base. The balance sheet also contracted: total assets and equity were both €3.0K in 2025, indicating a 100.0% equity ratio. Asset turnover was 1.49x in 2025, while ROE and ROA were both negative and reflected the loss-making year. Liabilities were €559 in 2023. Staff data was not provided, so revenue per employee cannot be assessed.